4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 性质
| 熔点 | 146-148°C |
|---|---|
| 沸点 | 543.4±60.0 °C(Predicted) |
| 密度 | 1.54±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.66±0.10(Predicted) |
| 颜色 | 白色至类白色 |
| InChI | 1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25) |
| InChIKey | NSQNZEUFHPTJME-UHFFFAOYSA-N |
| SMILES | NS(=O)(=O)c1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 用途与合成方法
|
COX-2 10 nM (IC 50 ) |
COX-1 17.8 μM (IC 50 ) |
SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage
viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.
Western Blot Analysis
| Cell Line: | vECs. |
| Concentration: | 15 μM |
| Incubation Time: | 30 min. |
| Result: | Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs. |
Western Blot Analysis
| Cell Line: | COS 7 cells. |
| Concentration: | 3 and 10 μM. |
| Incubation Time: | 18 h (combined with 15d-PGJ 2 ). |
| Result: | Acted in a concentration-dependent manner as a PPARγ agonist. |
SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.
| Animal Model: | Seventy-six male adult Wistar rats weighing 200-220 g (CCl 4 -treated). |
| Dosage: | 6 mg/kg. |
| Administration: | Orally, 3 times per week. |
| Result: |
A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats.
Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats. |
安全信息
| 危险品标志 | T |
|---|---|
| 危险类别码 | 25 |
| 安全说明 | 45 |
| 危险品运输编号 | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
| 存储类别 | 6.1C - 可燃，急性毒性 类别3 毒性化合物或者引起慢性影响的化合物 |
| 危险性类别 | 急性毒性 类别3经口 |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-07-06 | S0762 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- | 170569-86-5 | 5mg | 2841.93 |
| 2026-07-06 | S0762 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- | 170569-86-5 | 25mg | 8591.31 |
